The role of GDF-15 in heart failure patients with chronic kidney disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F19%3A00077846" target="_blank" >RIV/00023001:_____/19:00077846 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/19:43917906 RIV/00064190:_____/19:N0000065

Výsledek na webu

<a href="https://reader.elsevier.com/reader/sd/pii/S0828282X18313898?token=659ED51CEF7E79A092B69308852E0D3042A10B061D23D114D181B8CDC81139BBAE9B90DF27A4E2FE1AAF13B5B76C403C" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S0828282X18313898?token=659ED51CEF7E79A092B69308852E0D3042A10B061D23D114D181B8CDC81139BBAE9B90DF27A4E2FE1AAF13B5B76C403C</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.cjca.2018.12.027" target="_blank" >10.1016/j.cjca.2018.12.027</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The role of GDF-15 in heart failure patients with chronic kidney disease

Popis výsledku v původním jazyce

Background: Growth differentiation factor-15 (GDF-15) is a stressinducible cytokine and member of the transforming growth factor-b cytokine superfamily that refines prognostic assessment in subgroups of patients with heart failure (HF). We evaluated its role in HF patients with chronic kidney disease (CKD, estimated glomerular filtration rate &lt; 60 mL/min/1.73 m(2)). Methods: A total of 358 patients with stable systolic HF were followed for a median of 1121 (interquartile range, 379-2600) days. Comprehensive evaluation including B-type natriuretic peptide (BNP) and GDF15 testing was performed at study entry; the analysis was stratified according to kidney function. Results: Patients with CKD (33.8%) were older, had more often diabetes, and were less often treated with angiotensin converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB). GDF-15 was associated with estimated glomerular filtration rate, whereas BNP was associated with left ventricular-end diastolic diameter and ejection fraction (P &lt; 0.01). During follow-up, 244 patients (68.2%) experienced an adverse outcome 9death, urgent transplantation, implantation of mechanical circulatory support). In patients with HF and CKD, the Cox proportional hazard model identified BNP, GDF-15, sex, systolic blood pressure, sodium, total cholesterol, and ACEi/ARB treatment as significant variables associated with an adverse outcome 9P &lt; 0.05). In multivariable analysis, BNP was replaced by GDF-15. Net reclassification improvement confirmed prognostic superiority of the model encompassing GDF-15 9GDF-15, sodium, total cholesterol, ACEi/ARB treatment) compared with the model without GDF-15 9BNP, sex, sodium, ACEi/ARB treatment), net reclassification improvement 0.62, P = 0.005. In contrast, in patients with HF and normal kidney function, BNP remained superior to GDF-15 in a multivariable model. Conclusions: In patients with systolic HF and CKD, GDF-15 is more strongly associated with adverse outcomes than the conventionally used BNP.

Název v anglickém jazyce

The role of GDF-15 in heart failure patients with chronic kidney disease

Popis výsledku anglicky

Background: Growth differentiation factor-15 (GDF-15) is a stressinducible cytokine and member of the transforming growth factor-b cytokine superfamily that refines prognostic assessment in subgroups of patients with heart failure (HF). We evaluated its role in HF patients with chronic kidney disease (CKD, estimated glomerular filtration rate &lt; 60 mL/min/1.73 m(2)). Methods: A total of 358 patients with stable systolic HF were followed for a median of 1121 (interquartile range, 379-2600) days. Comprehensive evaluation including B-type natriuretic peptide (BNP) and GDF15 testing was performed at study entry; the analysis was stratified according to kidney function. Results: Patients with CKD (33.8%) were older, had more often diabetes, and were less often treated with angiotensin converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB). GDF-15 was associated with estimated glomerular filtration rate, whereas BNP was associated with left ventricular-end diastolic diameter and ejection fraction (P &lt; 0.01). During follow-up, 244 patients (68.2%) experienced an adverse outcome 9death, urgent transplantation, implantation of mechanical circulatory support). In patients with HF and CKD, the Cox proportional hazard model identified BNP, GDF-15, sex, systolic blood pressure, sodium, total cholesterol, and ACEi/ARB treatment as significant variables associated with an adverse outcome 9P &lt; 0.05). In multivariable analysis, BNP was replaced by GDF-15. Net reclassification improvement confirmed prognostic superiority of the model encompassing GDF-15 9GDF-15, sodium, total cholesterol, ACEi/ARB treatment) compared with the model without GDF-15 9BNP, sex, sodium, ACEi/ARB treatment), net reclassification improvement 0.62, P = 0.005. In contrast, in patients with HF and normal kidney function, BNP remained superior to GDF-15 in a multivariable model. Conclusions: In patients with systolic HF and CKD, GDF-15 is more strongly associated with adverse outcomes than the conventionally used BNP.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Canadian journal of cardiology

ISSN

0828-282X

e-ISSN

—

Svazek periodika

35

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

CA - Kanada

Počet stran výsledku

9

Strana od-do

462-470

Kód UT WoS článku

000462763000017

EID výsledku v databázi Scopus

2-s2.0-85063501937